{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T01:56:48Z","timestamp":1649123808211},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00393-012-0961-4","type":"journal-article","created":{"date-parts":[[2012,2,27]],"date-time":"2012-02-27T10:25:38Z","timestamp":1330338338000},"page":"127-137","source":"Crossref","is-referenced-by-count":3,"title":["\u00c4tiologie und Management der Gicht"],"prefix":"10.1007","volume":"71","author":[{"given":"B.","family":"Paz\u00e1r Maldonado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,29]]},"reference":[{"key":"961_CR1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum 63:3136\u20133141","journal-title":"Arthritis Rheum"},{"key":"961_CR2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","volume":"12","author":"Roddy","year":"2010","unstructured":"Roddy E, Doherty M (2010) Epidemiology of gout. Arthritis Res Ther 12:223\u2013234","journal-title":"Arthritis Res Ther"},{"key":"961_CR3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/art.21499","volume":"54","author":"Graessler","year":"2006","unstructured":"Graessler J, Graessler A, Unger S et al (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54:292\u2013300","journal-title":"Arthritis Rheum"},{"key":"961_CR4","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","volume":"372","author":"Dehghan","year":"2008","unstructured":"Dehghan A, Kottgen A, Yang Q et al (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372:1953\u20131961","journal-title":"Lancet"},{"key":"961_CR5","doi-asserted-by":"crossref","first-page":"e1000504","DOI":"10.1371\/journal.pgen.1000504","volume":"5","author":"Kolz","year":"2009","unstructured":"Kolz M, Johnson T, Sanna S et al (2009) Metaanalysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5:e1000504","journal-title":"PLoS Genet"},{"key":"961_CR6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/hmg\/ddp489","volume":"19","author":"Harst","year":"2010","unstructured":"Harst P van der, Bakker SJ, Boer RA de et al (2010) Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet 19:387\u2013395","journal-title":"Hum Mol Genet"},{"key":"961_CR7","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ard.2009.109355","volume":"68","author":"Torres","year":"2009","unstructured":"Torres R, Macdonald L, Croll SD et al (2009) Hyperalgesia, synovitis, and multiple biomarkers of inflammation are suppressed by IL-1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 68:1602\u20131608","journal-title":"Ann Rheum Dis"},{"key":"961_CR8","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/art.10326","volume":"46","author":"Schiltz","year":"2002","unstructured":"Schiltz C, Liot\u00e9 F, Prudhommeaux F et al (2002) Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum 46:1643\u20131650","journal-title":"Arthritis Rheum"},{"key":"961_CR9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"Martinon","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237\u2013241","journal-title":"Nature"},{"key":"961_CR10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.0105-2896.2009.00860.x","volume":"233","author":"Martinon","year":"2010","unstructured":"Martinon F (2010) Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 233:218\u2013232","journal-title":"Immunol Rev"},{"key":"961_CR11","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/art.27667","volume":"62","author":"Joosten","year":"2010","unstructured":"Joosten LA, Netea MG, Mylona E et al (2010) Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1\u03b2 production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 62:3237\u20133248","journal-title":"Arthritis Rheum"},{"key":"961_CR12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT et al (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895\u2013900","journal-title":"Arthritis Rheum"},{"key":"961_CR13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301\u20131311","journal-title":"Ann Rheum Dis"},{"key":"961_CR14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/art.1780390820","volume":"39","author":"Gerster","year":"1996","unstructured":"Gerster JC, Landry M, Duvoisin B, Rappoport G (1996) Computed tomography of the knee joint as an indicator of intraarticular tophi in gout. Arthritis Rheum 39:1406\u20131409","journal-title":"Arthritis Rheum"},{"key":"961_CR15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/rheumatology\/kem058","volume":"46","author":"Thiele","year":"2007","unstructured":"Thiele RG, Schlesinger N (2007) Ultrasonography is a reliable, non-invasive method for diagnosing gout. Rheumatology 46:1116\u20131121","journal-title":"Rheumatology"},{"key":"961_CR16","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1148\/rg.315115510","volume":"31","author":"Desai","year":"2011","unstructured":"Desai MA, Peterson JJ, Garner HW, Kransdorf MJ (2011) Clinical utility of dual-energy CT for evaluation of tophaceous gout. Radiographics 31:1365\u20131375","journal-title":"Radiographics"},{"key":"961_CR17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/ard.61.1.52","volume":"61","author":"Gerster","year":"2002","unstructured":"Gerster JC, Landry M, Dufresne L, Meuwly JY (2002) Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis 61:52\u201354","journal-title":"Ann Rheum Dis"},{"key":"961_CR18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","volume":"49","author":"Man","year":"2007","unstructured":"Man CY, Cheung IT, Cameron PA, Rainer TH (2007) Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute gout like arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 49:670\u2013677","journal-title":"Ann Emerg Med"},{"key":"961_CR19","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62:1060\u20131068","journal-title":"Arthritis Rheum"},{"key":"961_CR20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312\u20131324","journal-title":"Ann Rheum Dis"},{"key":"961_CR21","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1002\/art.27641","volume":"62","author":"Liot\u00e9","year":"2010","unstructured":"Liot\u00e9 F (2010) Advances in the proper use of colchicine and adapting dosages in other countries: comment on the article by Terkeltaub et al. Arthritis Rheum 62:3126\u20133127 (author reply 3127\u20133128)","journal-title":"Arthritis Rheum"},{"key":"961_CR22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"Stamp","year":"2011","unstructured":"Stamp LK, O\u2019Donnell JL, Zhang M et al (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63:412\u2013421","journal-title":"Arthritis Rheum"},{"key":"961_CR23","unstructured":"Pascual E, Sivera F, Tekstra J, Jacobs J (2009) Crystal arthropathies and septic arthritis. In: EULAR compendium on rheumatic diseases. BMJ, London, pp\u00a0132\u2013139"},{"key":"961_CR24","doi-asserted-by":"crossref","unstructured":"Schumacher HR, Becker MA, Lloyd E et al (2009) Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48:188\u2013194","DOI":"10.1093\/rheumatology\/ken457"},{"key":"961_CR25","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63","journal-title":"Arthritis Res Ther"},{"key":"961_CR26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","volume":"47","author":"Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Garc\u00eda-Erauskin G et al (2002) Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 47:610\u2013613","journal-title":"Arthritis Rheum"},{"key":"961_CR27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","volume":"25","author":"Moolenburgh","year":"2006","unstructured":"Moolenburgh JD, Reinders MK, Jansen TL (2006) Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 25:749\u2013752","journal-title":"Clin Rheumatol"},{"key":"961_CR28","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","volume":"58","author":"Sundy","year":"2008","unstructured":"Sundy JS, Becker MA, Baraf HS et al (2008) Pegloticase Phase 2 Study Investigators. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 58:2882\u20132891","journal-title":"Arthritis Rheum"},{"key":"961_CR29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11926-010-0093-2","volume":"12","author":"Schlesinger","year":"2010","unstructured":"Schlesinger N (2010) New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. Curr Rheumatol Rep 12:130\u2013134","journal-title":"Curr Rheumatol Rep"},{"key":"961_CR30","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1002\/art.25006","volume":"60","author":"Joosten","year":"2009","unstructured":"Joosten LA, Netea MG, Fantuzzi G et al (2009) Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 60:3651\u20133662","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-012-0961-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-012-0961-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-012-0961-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T12:31:34Z","timestamp":1561379494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-012-0961-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1007\/s00393-012-0961-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}